News coverage

Dr Marlyn Mayo and Dr Andreas Kremer share key insights on primary sclerosing cholangitis from AASLD The Liver Meeting 2025, and explore the latest in therapeutic developments and symptomatology.

Marlyn Mayo discusses findings on physician attitudes to managing pruritus in PSC.

A real-world analysis of PSC patients given maralixibat suggests it offers meaningful improvements in pruritus.

Marios Nikolaidis shares findings on the gut microbiome in PSC management.

A mind–body intervention accessed online may help patients with liver disease better manage their symptoms.

Mitchell Shiffman comments on ELMWOOD findings for elafibranor in PSC.

US researchers have found that the numerous and potentially distressing symptoms of PSC fit into four clear profiles.

Natural language programming could help identify which adults with cholestasis have late-onset progressive familial intrahepatic cholestasis.

An open-label trial extension showed that the PPAR agonist elafibranor maintained efficacy, and former placebo patients saw improvements.

Dr Marlyn Mayo and Dr Andreas Kremer discuss what’s ahead at AASLD 2025, with a focus on advances in primary biliary cholangitis and primary sclerosing cholangitis. They share their perspectives on emerging research, key topics to watch, and what they are most looking forward to at this year’s meeting.